Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 16Urethral Neoplasms 4Prostatic Neoplasms 4Testicular Neoplasms 3Testicular Germ Cell Tumor 2Teratoma 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Urothelial Carcinoma of the Bladder 1Ureteral Neoplasms 1Seminoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Neoplasm Metastasis 1Muscle Invasive Bladder Urothelial Carcinoma 1Endodermal Sinus Tumor 1Carcinoma, Transitional Cell 1Carcinoma, Embryonal 1Bladder Adenocarcinoma 1

Interventions

Gemcitabine 11pembrolizumab 8enfortumab vedotin 8Specimen Handling 8Cisplatin 8Magnetic Resonance Spectroscopy 6avelumab 5Carboplatin 5vinflunine 4Nivolumab 4atezolizumab 3Biopsy 3cabozantinib 2Standard of Care 2Ramucirumab 2Platinum 2Ipilimumab 2Immunoglobulin G 2Doxorubicin 2Docetaxel 2Disulfides 2CTLA-4 Antigen 2Bortezomib 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1tocilizumab 1tamibarotene 1rucaparib 1relatlimab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ureteral Neoplasms × Vinblastine × Genitourinary × Clear all
NCT01639521 2014-01-29

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

University of Southern California

Phase 2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡